Obinutuzumab in two patients suffering from immune‐mediated thrombotic thrombocytopenic purpura intolerant to rituximab
Judith Robertz(University of Bern), Johanna A. Kremer Hovinga(University of Bern), Irene Koneth(University of St.Gallen), Isabelle Binet(Kantonsspital St. Gallen), Martin Andres(University of Bern), Behrouz Mansouri Taleghani(University of Bern)
Cited by 13
Related Papers
Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence
|New England Journal of Medicine|2023|128
Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion
|Archives of Gynecology and Obstetrics|2019|96
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
|Leukemia|2021|94
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia
|The American Journal of Medicine|2003|72
Familial Clustering of High Factor VIII Levels in Patients With Venous Thromboembolism
|Arteriosclerosis Thrombosis and Vascular Biology|2001|70